Market Trends of Protein Crystallization Industry
The Pharmaceuticals and Biotechnology Industries Segment is Expected to Hold a Significant Market Share in the Protein Crystallization Market
The pharmaceutical and biotechnology industries are expected to be the most lucrative segment, with extensive usage of protein crystallization in the production process. The pharmaceutical and biotech industry is expected to register significant revenue growth over the forecast period owing to the increasing application of protein crystallization in the drug discovery and development process, rising demand for protein therapeutics, and the fundraising of biotech companies.
The increasing number of innovative product launches to meet the growing demand is also expected to boost the market segment's growth. For instance, in July 2021, DeepMind signed a partnership with the European Molecular Biology Laboratory (EMBL) to create the most complete and accurate database of predicted protein structure models for the human proteome. The partnership aims to cover all ~20,000 proteins expressed by the human genome, and this data is to be freely and openly available to the scientific community. Additionally, in July 2022, Redwire Corporation reported that it would be developing new in-space manufacturing technology to provide novel and flexible services to grow small-batch crystals of protein-based pharmaceuticals and other key pharmaceutically relevant molecules for research and production. Such launches and developments are propelling the growth of the market.
Furthermore, the growing expansion of facilities by pharmaceutical and biotechnological companies to meet the increasing demand for protein crystallization is also boosting the growth of the segment. For instance, in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.48 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourney Biologics S.A. Such initiatives taken by the market players help in the increased adoption of protein crystallization techniques, thereby propelling the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to project growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant share of the global market owing to technological innovations in protein crystallization and an increase in research and development activities in the biopharma sector. The robust growth of protein crystallization can be attributed to the increasing investment and funding activities for proteomics research and the development of structure-based drugs.
The increase in research and development activities and collaboration among the market players and research institutes contribute to the growth of the overall regional market. For instance, in January 2022, Cullinan Oncology Inc. collaborated with the Icahn School of Medicine at Mount Sinai ("Icahn Mount Sinai") to develop novel small-molecule immune modulators. The multi-year collaboration agreement will focus on optimising and developing oral protein degraders targeting hematopoietic progenitor kinase 1 (HPK1), a key regulator of immune cell activation and a high-priority target in immune oncology. Such research agreements create the need for these products for protein crystallization and thus are expected to propel market growth.
Furthermore, in October 2021, EQRx and Absci Corporation signed a partnership agreement to discover and develop next-generation protein-based drugs. As per the agreement, both organizations leverage Absci's Drug Creation technology for discovery and development activities and EQRx's clinical development expertise and commercial capabilities to advance next-generation, protein-based therapeutics across multiple therapeutic areas, including oncology and immunology.
Thus, the market is expected to grow in the North American region over the forecast period due to rising research and development of protein based drugs.
